The public is told that modern medicine rests on rigorous science, impartial research and evidence-based decision making. But critics argue that the reality is often far less reassuring.
According to an investigation based on the work of commentator A Midwestern Doctor, the outcome of many clinical trials may be influenced long before results ever reach the public. Trial design, participant selection, statistical methods and publication practices can all shape the final conclusions, raising questions about how much trust should be placed in the studies that underpin modern healthcare.
One example cited is an unpublished study comparing vaccinated and unvaccinated children. The study reportedly found higher rates of several chronic health conditions among vaccinated children, including asthma, autoimmune disorders and developmental issues. Despite an earlier commitment to publish the findings regardless of outcome, the research was never released, with concerns reportedly raised about the professional consequences of publishing controversial results.
The report argues that such cases are part of a broader problem. Pharmaceutical companies largely fund the expensive randomized controlled trials that regulators and medical journals regard as the highest standard of evidence. Because these studies often cost tens of millions of dollars, critics contend that only large corporations can afford to determine which treatments receive the research necessary for widespread acceptance.
A Midwestern Doctor points to several techniques that can influence trial outcomes. These include comparing new products against weak or inappropriate alternatives, excluding participants likely to experience side effects, relying on surrogate markers rather than meaningful health outcomes, shortening safety monitoring periods, and selectively reporting favourable results. Critics say these practices can create the appearance of effectiveness or safety while obscuring important risks.
The report also revisits controversies surrounding the COVID-19 pandemic, arguing that low-cost treatments often received less institutional support than expensive patented medicines. It further questions whether financial relationships between regulators, pharmaceutical companies and research institutions create conflicts of interest that undermine public confidence in medical science.
Supporters of randomised controlled trials maintain they remain one of the most valuable tools available for assessing medical treatments. However, the report concludes that transparency, independent scrutiny and access to underlying data are essential if public trust is to be maintained. Without those safeguards, critics warn that evidence-based medicine risks becoming less about discovering what works and more about protecting commercial interests.
In a nutshell the peer review system is compromised and broken.